MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Sarepta Therapeutics Inc

Closed

SectorHealthcare

58.19 -6.75

Overview

Share price change

24h

Current

Min

57.47

Max

62.01

Key metrics

By Trading Economics

Income

125M

159M

Sales

191M

658M

P/E

Sector Avg

27.274

63.778

EPS

1.9

Profit margin

24.156

Employees

1,372

EBITDA

138M

187M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+164.8% upside

Dividends

By Dow Jones

Next Earnings

30 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-3.8B

6.8B

Previous open

64.94

Previous close

58.19

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Sarepta Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 cze 2024, 23:05 UTC

Major Market Movers

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 cze 2024, 08:58 UTC

Top News

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Peer Comparison

Price change

Sarepta Therapeutics Inc Forecast

Price Target

By TipRanks

164.8% upside

12 Months Forecast

Average 165.42 USD  164.8%

High 215 USD

Low 75 USD

Based on 20 Wall Street analysts offering 12 month price targets forSarepta Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

16

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

61.525 / 72.17Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.